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A B S T R A C T
Magnusiomyces clavatus is an ascomycetous fungus causing invasive disease in immuno-compromised patients.
Neutropenia, contaminated venous catheters, previous antifungal treatment are risk factors for this infection. We
report a case of Magnusiomyces clavatus fungemia with pulmonary, renal and skin localizations in a 6-year-old
boy with prolonged neutropenia because of three allogeneic hematopoietic stem cell transplantations. The in-
fection was controlled by aggressive and strictly monitored combination therapy with voriconazole and lipo-
somial-ampthotericine-B along with durable recover from neutropenia.
1. Introduction
Magnusiomyces clavatus (M. clavatus), formerly known as Geotrichum
clavatum, is an ascomycetous fungus, that has been described as a rare
cause of invasive fungal disease (IFD) in immuno-compromised patients
[1,2]. Profound and prolonged neutropenia is a requisite for M. clavatus
fungemia, which may lead to multiple organ localizations (1). Other
risk factors, like contaminated venous catheters or previous antifungal
treatment, have been also associated with this infection [3,4]. Clusters
have been reported in hematological settings through Europe, but no
clear source of infection has been found yet, due to its natural presence
in human ﬂora, soil and dietary products, as some kinds of milky-
cheeses [2,3]. Poor outcome has been described with this pathogen (1),
since no satisfy antifungal regimen has been found yet [5].
Approximately one hundred cases of IFD due to M. clavatus have
been reported in adults, while only few cases of Magnusiomyces capi-
tatus (Saprochaete capitata) fungemia have been described in children
[1–3,6,7].
We describe the ﬁrst pediatric case of M. clavatus fungemia with
organ dissemination occurred in a neutropenic patient between the
second and the third allogeneic hemopoietic stem cell transplantation
(HSCT) performed in a tertiary Italian pediatric Research Institute.
2. Case
A 6-year-old boy, aﬀected by bone marrow failure, received a ﬁrst
haploidentical stem cell transplantation using α/β/CD19 depleted
peripheral blood stem cells from his mother, after conditioning regimen
including Fludarabine, Cyclophosphamide, low-dose of Total Body
Irradiation, anti-thymocyte globulin, and Rituximab. His brother was
excluded as a donor due to abnormalities in granulocytes colonies’
growth.
On day + 24 after HSCT, rejection was documented and a second
haploidentical HSCT was performed 16 days later. In this case, the
patients received anti-mycotic prophylaxis with liposomal amphoter-
icin B (LAMB) at 2.5mg/kg two times a week, according to our stan-
dard protocol in cases of HSCT reject. In this case conditioning regimen
included Fludarabine, Melphalan, Alemtuzumab, and Rituximab. The
day after infusion the patient developed fever, empirically treated with
piperacillin/tazobactam and amikacin, waiting for the culture results.
Blood cultures were positive for yeasts subsequently identiﬁed as M.
clavatus by molecular identiﬁcation. In particular, the extracted
genomic DNA was ampliﬁed using the universal fungal-speciﬁc primers
ITS1 (TCCGTAGGTGAACCTGCGG) and ITS4 (TCCTCCGCTTATTGATA
TGC) for internal transcribed spacer regions of fungal ribosomal DNA
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and nucleotide sequences were analyzed using Finch TV software
Version 1.4.0. (www.geospizia.com) [8]. We inserted sequences in
GeneBank (accession number of the closest hit in GenBank MF142803.
1), but at the moment we do not yet have the datum related to the
strain.
Antifungal susceptibility test performed by broth microdilution
assay (Sensititre™ YeastOne - TREK Diagnostic Systems, Cleveland, OH,
USA) according to manufacturer's indications, showed the following
minimal inhibitory concentrations (MIC mg/L): amphotericin B (AMB)
1, caspofungine> 8, ﬂuconazole 64, voriconazole 1, ﬂucytosine 0.5.
No standardized MICs interpretation is currently available for this pa-
thogen [9].
AMB dose was increased to 3mg/kg daily, but blood cultures re-
mained positive. Substitution of intravascular access was performed but
nodular lesions on the chin and left arm appeared, associated with
pulmonary nodules and kidney's lesions (Fig. 1), seven days after the
fever. The removed central venous line was cultured without growth of
M. clavatus. Echocardiography was normal.
On day +9 after HSCT, voriconazole at 9mg/Kg for 2 doses and
then 8mg/Kg twice daily was added. Skin biopsy was not diagnostic
but compatible with generic inﬂammation. Unfortunately the patient
developed another HSCT rejection. Therefore the patient received a 3rd
HSCT, from his HLA identical brother, after a secondary assessment to
exclude abnormalities of granulocytes colonies growth. The con-
ditioning regimen included Fludarabine, Treosulphan, ATG, and cy-
closporine. Full donor engraftment occurred regularly, but blood cul-
tures remained persistently positive for M. clavatus. Plasmatic level of
liposomal amphotericin B and voriconazole were 7.4mg/L (peak) and
3.5 mg/L (trough) respectively. LAMB was increased to 5mg/Kg and
then to 10mg/Kg/day, with the aim to increase the Cmax/MIC ratio,
while voriconazole dosage was unchanged since its plasma concentra-
tions were considered in the therapeutic range, at least comparing with
other fungi, as Aspergillus. Blood cultures remained positive for M.
clavatus until day + 10 from the 3rd HSCT that corresponded to neu-
trophils engraftment and later blood cultures became negative.
Combination treatment with LAMB and voriconazole was prolonged for
1 month after negativity of blood culture, and voriconazole 8mg/kg
was maintained for other 4 months. During this period the clinical,
hematological and radiological pictured improved. Eight months after
the end of antifungal treatment the patient was still on treatment with
cyclosporine with complete engraftment (100% donor) and no signs of
IFD was demonstrated.
3. Discussion
This case report represent the ﬁrst description of IFD due to M.
clavatus in paediatrics.
Profound and prolonged neutropenia due to recurrent HSCT rejec-
tions was probably the most important risk factor for the development
and persistence of this infection, since cultures of all vascular accesses
removed were negative and the persistence of fungemia was related
with documented organ localizations.
No known dietary products containing cheese, possibly con-
taminated by the fungus, were identiﬁed in the patient's daily diet,
although it cannot be excluded.
Low dose liposomal amphotericin B, suggested as a possible pro-
phylaxis of IFD in pediatric allogeneic HSCT (at least for aspergillosis),
was not eﬀective to prevent this infection.
Fig. 1. Panel A: Pulmonary localization of S. clavata. Panel B: Multiple bilateral renal lesions due to S. clavata. Panel C: Multiple skin localization of S. clavata.
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Susceptibility to antifungal drugs of M. clavatus has been reported
from in vitro studies [1–5,10]. In absence of any standardized break-
point we adopted a treatment strategies with full doses of antifungal
drugs and plasma levels evaluation, similar to that suggested for other
fungi and a combination of liposomal amphotericin B (at increasing
doses) and voriconazole, that in some way resulted eﬀective in limiting
the containing spreading at least until neutrophils recovery, that seems
to have been pivotal for patient's ﬁnal recovery [10]. Disseminated IFD
due to M. clavatus is associated with high morbidity and mortality [2].
In this case combination therapy with LAMB and voriconazole seemed
more eﬀective to limit the infection and in our patient did not lead to
any organ toxicity [1–11].
Finally, high level of awareness, a strict policy of high-risk patients’
contact-isolation even before pathogen identiﬁcation, as well as a rapid
fungal diagnostic avoided a possible healthcare-associated outbreak
[12].
No certain data about combination therapy vs mono-therapy and
length of treatment are available yet. In our case aggressive and strictly
monitored combination treatment along with durable recover from
neutropenia seemed to be useful to control the infection.
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